Search

Introduction: There exists a current growth of urinary tract infections in kidney transplant recipients caused by multidrug-resistant organisms (MRO), which has become a medical challenge. Objective: To describe the prevalence of urinary tract infection (UTI) from MRO in hospitalized kidney transplant recipients (KTR), their risk factors, treatment and evolution at 1 year. Methods: Clinical records and cultures of hospitalized KTR infected by MRO were reviewed between January 1st 2016 and Dec. 31st 2017. The following risk factors were evaluated: gender, advanced age, prolonged presence of double-J stent, surgical complications and long-term hospitalization, renal function at the time of admission, at discharge and at one year, and the appearance of any rejection after one year. Results: The presence of multiresistant germs was found in 58 KTR (31.18%), who presented 105 episodes of UTI; 36 of them had a single infection and 22 suffered more than one. 55.17% (32) were men and the average age was 50.52 ± 14.24 years. Of the total of patients, 43 (74.15%) had these risk factors: late extraction of double-J stent in 8 patients (13.8%), surgical complications in 11 (18.9%), long-term hospitalization in 12 (20, 7%) and 18 (31.03%) were older than 60. During evolution, 9 patients required dialysis, 4 of which recovered their renal function. The creatinine at the time of admission of the patients who did not need dialysis was 1.8 (1.39 - 3.01) mg/dL; at discharge it was 1.5 (1.1 - 2.1) mg/dL (p = 0.025) and after one year it was 1.5 (1.18 - 2.1) mg/dL without significant difference with respect to discharge (p = 0.089). In the annual follow-up, 5 patients died and 5 lost the transplant. The incidence of rejection was 15.51%. The presence of risk factors and recurrent and / or recurrent ITUs did not result in significant differences in renal function at follow-up, nor in patient and graft survival. The following germs were found: 13 A. baumannii cpx. (ABA) (11.92%); 24 E. Coli (ECO) (22.01%); 4 Enterobacter spp. (3.66%), 3 Enterococcus spp. (2.75%); 58 Klebsiella spp. (53.21%); 5 Serratia spp. (4.58%); 1 Proteus spp. (0.91%), and 1 Pseudomonas aeruginosa (PAE) (0.91%). Of the 105 episodes of UTI, 79 were treated with monotherapy: 57 with carbapenem (54.28%), 10 with colistin (9.51%), 4 with linezolid (3.8%), 4 with piperacillin + tazobactan (3.8%), 3 with ciprofloxacin (2.85%) and 1 with nitrofurantoin (0.95%). In 26 episodes, combined therapies of carbapenem were used in 21 cases; colistin in 14; amikacin in 13; fosfomycin in 2, and on one occasion tigecycline was used and in another, ciprofloxacin. Conclusion: The urinary tract infections caused by MRO were frequent and similar to those described in other series. No differences were found in the evolution of renal function, in rejections, in mortality in UTI due to MOR with or without associated risk factors, neither of recurrent UTIs influence or relapsing observed were found. Further studies with a larger number of patients are necessary to evaluate the prognosis and evolution of patients with these infections.

Introduction: Delayed graft function (DGF) is a common complication in renal transplant and has implications for its development. Objectives: To know its incidence in a single transplant center, to describe the risk factors in donor and recipient, the procedure and the evolution of the graft and recipient. Methods: 178 renal transplant patients (P) with grafts from cadaveric donors were studied. Delayed graft function was defined as dialysis requirement in the first week post transplantation. We analyzed risk factors in the donor and recipient as well as the transplant procedures. Results: DGF incidence was 75.8% (135 patients). Risk factors for DGF were: greater cold ischemia time in minutes (1389 vs. 1224; P=0.01), greater recipient’s age in years (47.24 vs 40.71; P=0.001) and greater BMI of the donor (27.5 vs 25.17; P= 0.001). In 170 patients the presence of rejection was evaluated: those who had DGF presented more rejections (35.6% vs. 19.5%; P=0.046). The group with DGF showed lower graft survival at 5 years (P=0.0473), there was no difference in patient survival. Conclusion: The DGF incidence is higher than reported in the literature. Efforts should be made to reduce its incidence, focusing in reducing cold ischemia and improving maintenance of the donor.